Free Trial
OTCMKTS:ALPMY

Astellas Pharma 2/5/2024 Earnings Report

Astellas Pharma logo
$9.66 -0.16 (-1.63%)
As of 03:58 PM Eastern

Astellas Pharma EPS Results

Actual EPS
$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Astellas Pharma Revenue Results

Actual Revenue
$2.86 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Astellas Pharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Astellas Pharma's next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules.

Conference Call Resources

Astellas Pharma Earnings Headlines

ALPMY Astellas Pharma Inc. - Seeking Alpha
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Astellas Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email.

About Astellas Pharma

Astellas Pharma (OTCMKTS:ALPMY) is a global pharmaceutical company headquartered in Tokyo, Japan, with operations spanning North America, Europe, Asia-Pacific, Latin America and the Middle East. Formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has since established a solid presence in prescription drug research, development and commercialization. The company focuses on advancing therapies in oncology, urology, immunology, nephrology and neuroscience, aiming to deliver innovative solutions that address unmet medical needs.

Astellas’ product portfolio includes treatments for a wide range of conditions. Its oncology franchise features Xtandi (enzalutamide) for prostate cancer and PADCEV (enfortumab vedotin-ejfv) for urothelial cancer, both of which have become cornerstones of the company’s cancer pipeline. In urology, the company markets Myrbetriq (mirabegron) and Vesicare (solifenacin) to manage overactive bladder symptoms. Immunosuppressants such as Prograf (tacrolimus) and Astagraf XL also play key roles in the company’s offerings for organ transplant recipients.

Research and development is central to Astellas’ growth strategy. The company invests in next-generation modalities including gene therapy, cell therapy and targeted radiopharmaceuticals. Astellas maintains a network of research centers and partnerships worldwide to accelerate discovery and clinical trials, with a particular emphasis on precision medicine and regenerative solutions. This commitment to R&D has yielded a robust pipeline of investigational compounds across multiple therapeutic areas.

Under the leadership of President and CEO Naoki Okamura, Astellas aims to strengthen its global footprint and foster collaboration with academic institutions, biotech firms and healthcare providers. The management team emphasizes corporate responsibility, sustainability and patient-centric initiatives, ensuring that the company’s innovations contribute to better health outcomes and social value around the world.

View Astellas Pharma Profile

More Earnings Resources from MarketBeat